Deals
Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.
FEATURED STORIES
After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years.
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
SkinBioTherapeutics plc, a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
The early-stage biotech company, previously named FLX Bio, plans to raise up to $86 million with the IPO. It plans to trade on the Nasdaq under the ticker symbol RAPT.
Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.
Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
Fusion Antibodies plc announces its final results for the year ended 31 March 2019.
BioArctic AB to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 11, 2019 at 08:00 a.m. CET.
Chignolo D’Isola, Bergamo, Italy – July 1, 2019 – Flamma SpA, a preeminent Contract Development and Manufacturing Organization that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients for the pharmaceutical industry, is proud to announce that the company has acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area.
Novartis announced that it has completed its acquisition of Xiidra® 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.